IDYA and Servier dose first patient in OptimUM-11 Phase 3 uveal melanoma trial
IDEAYA Biosciences and Servier announced the first patient was dosed in OptimUM-11, a Phase 3 registrational trial evaluating darovasertib and crizotinib as adjuvant therapy for uveal melanoma.